[Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma].

Abstract

BACKGROUND:

The aim of this study is to detect the BIM polymorphism in 85 formalin-fixed and parrffin-embedded (FFPE) and some blood samples of advanced lung adenocarcinoma patients and study the relativity betweenthe BIM polymorphism and tyrosine kinase inhibitor (TKI). The correlation between BIM detection of different types of specimens was discussed.

METHODS:

There were 85 patients who were diagnosed as advanced lung adenocarcinoma with epidermal growth factor receptor (EGFR) 19 or 21 exon mutation in thoracic surgery of Xuanwu Hospital from February 2013 to November 2014, all of who were received EGFR-TKI as first-line treatment in the study. FFPE and some blood were used to detect the BIM polymorphism. The objective response rate (ORR) and progression-free survival (PFS) of two groups were compared. According to smoking, sex, EGFR mutation and other factors, the single factor analysis was performed, and the correlation between paraffin samples and blood test BIM was compared.

RESULTS:

The ORR in BIM polymorphism and non-polymorphism groups was no significant differences (P>0.05). The median PFS in BIM polymorphism and non-polymorphism group was 7.1 months and 12.8 months, respectively (P=0.013). Univariate analysis the median PFS, women were longer than men (12.1 months vs 10.7 months, P=0.835); Non-smokers were longer than smokers (12.1 months vs 9.7 months, P=0.974). Group in EGFR exon 21 is longer than group in EGFR exon 19 (12.2 months vs 8.7 months, P=0.303).

CONCLUSIONS:

Detection of BIM gene polymorphism in lung cancer patients with EGFR-TKIs treatment might be helpful for predicting prognosis. But a large sample study is needed.

• Authors: Kun Qian, Yi Zhang, Xiuyi Zhi
• Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer (Zhongguo Fei Ai Za Zhi) Vol. 20 Issue 8 Pg. 543-548 (Aug 20 2017) ISSN: 1999-6187 [Electronic] China
• PMID: 28855035 (Publication Type: Journal Article)

Chemical References

• Bcl-2-Like Protein 11
• Protein Kinase Inhibitors
• EGFR protein, human
• ErbB Receptors

Topics

• Adenocarcinoma (drug therapy, enzymology, genetics)
• Adenocarcinoma of Lung
• Adult
• Aged
• Aged, 80 and over
• Bcl-2-Like Protein 11 (genetics)
• ErbB Receptors (antagonists & inhibitors, genetics, metabolism)
• Exons
• Female
• Humans
• Lung Neoplasms (drug therapy, enzymology, genetics)
• Male
• Middle Aged
• Mutation
• Polymorphism, Genetic
• Protein Kinase Inhibitors (administration & dosage)
• Retrospective Studies